Verified factor-similar pair

SYLD vs XMVM

These two ETFs meet the same FF6 US comparison criteria: US-listed equity ETFs, the same USD model basis, at least one material non-market factor, and 100% overlap in statistically significant material factor exposure.

SMB HML RMW
Similarity score
83
Verified similar

The score combines exposure-level distance, factor-vector shape, market-beta closeness, and a small backtested relative-Sharpe term.

Quick Read

  • SYLD has the higher backtested relative Sharpe (1.245 vs 0.999).
  • XMVM has the lower published fee (0.41% vs 0.59%).
  • XMVM is cheaper on dividend valuation (98 vs 128, where 100 is each fund's historical median).
  • XMVM has the stronger regression fit (adjusted R-squared 0.899 vs 0.888).

These are screening signals, not a complete review of portfolio construction, turnover, taxes, or trading quality.

SYLD

Cambria Shareholder Yield ETF
SMB HML RMW
Adj. R2
0.888
Rel. Sharpe
1.245
Mkt beta
1.02
AUM
US$922M
MER
0.59%
Valuation
128

XMVM

Invesco S&P MidCap Value with Momentum ETF
SMB HML RMW
Adj. R2
0.899
Rel. Sharpe
0.999
Mkt beta
0.98
AUM
US$435M
MER
0.41%
Valuation
98

Factor Exposure Match

Blue bars compare raw factor beta magnitude. Green bars compare absolute t-stat strength. Dim bars indicate the t-stat is below 1.96.

SMB
SYLD
+0.60
|t|
+8.9
XMVM
+0.46
|t|
+9.4
diff +0.14
HML
SYLD
+0.37
|t|
+5.7
XMVM
+0.34
|t|
+7.0
diff +0.03
RMW
SYLD
+0.25
|t|
+3.2
XMVM
+0.25
|t|
+4.3
diff -0.00
CMA
SYLD
+0.19
|t|
+2.0
XMVM
+0.04
|t|
+0.6
diff +0.15
UMD
SYLD
+0.00
|t|
+0.1
XMVM
-0.06
|t|
-2.1
diff +0.06

Why This Pair Matches

Exposure level
80
Exposure shape
99
Mkt beta diff
0.05
Rel. Sharpe diff
0.246

This comparison focuses on measured factor exposure. It does not compare holdings methodology, turnover, tax handling, or issuer process. Backtested relative Sharpe is a secondary signal rather than a stand-alone forecast. See methodology.

SYLD fund page XMVM fund page US ETF Leaders US Universe
Important context

VerifiedBeta publishes educational ETF research, not personalized investment advice, portfolio management, or security recommendations. Funds that screen well here can still be unsuitable for your objectives, taxes, liquidity needs, or constraints. Review fund documents, methodology assumptions, and your own circumstances before acting. See the full disclaimer.